Gland Pharma Reports Sustainability Milestones in Pharmaceutical Operations for FY2025-26

Gland Pharma Reports Sustainability Milestones in Pharmaceutical Operations for FY2025-26​

Gland Pharma Limited, a major player in the pharmaceutical industry, has published its Business Responsibility and Sustainability Report (BRSR) covering the financial year 2025-26. The report outlines the company’s operational scope, commitment to environmental stewardship, and social welfare initiatives across its manufacturing and research and development activities.

The company remains committed to sustainable practices, particularly noting significant steps taken towards reducing its carbon footprint and improving resource efficiency in its manufacturing processes.

Operational Scope and Market Reach​

Gland Pharma’s core business involves the pharmaceutical research and development, manufacturing, and marketing of complex injectables. The company's portfolio includes generic formulations, representing 100% of sales for this segment.

Operating both nationally and internationally, Gland Pharma serves markets across 20 states in India and 60 countries globally. Exports constitute a substantial portion of the business, making up 88.44% of the total turnover.

The company’s workforce totals 4,295 employees as of March 31, 2026, with 3,764 being permanent employees (representing 88%). The organization also manages a team of 37 workers.

Environmental Stewardship and Resource Management​

In an effort to enhance its environmental performance, Gland Pharma has made notable improvements to its operations. The company successfully transitioned its manufacturing facilities from furnace oil to piped natural gas (PNG) as boiler fuel, which contributed significantly to reducing stack emissions and lowering CO2 output. Furthermore, the company implemented a robust occupational health and safety management system compliant with ISO 45001 standards.

The company has demonstrated dedication to water conservation, including improvements made to its raw water underground storage tanks that have led to a notable reduction in overall water consumption. The facilities also maintain strict effluent management protocols; the Pashamylaram Facility operates a Zero Liquid Discharge (ZLD) system with complete water recovery and reuse, while other sites manage treated effluent through authorized Central Effluent Treatment Plants (CETPs).

Ethical Governance and Employee Welfare​

Gland Pharma emphasizes ethical conduct and employee well-being across its operations. The company maintains a robust anti-corruption and anti-bribery policy, accessible publicly. There were no instances recorded where disciplinary action was taken against directors or Key Managerial Personnel for corruption or bribery during FY2025-26.

From an human rights perspective, the company ensures that all employees receive comprehensive training on matters such as the Code of Conduct, Prevention of Sexual Harassment at the Workplace (POSH), and Prohibition of Insider Trading. The company’s commitment to fair labor practices is highlighted by the finding that 100% of permanent workers are covered by Employee State Insurance (ESI) for both FY2025-26 and FY2026, with a smaller percentage being covered under Health Insurance in some periods.

The company maintains mechanisms to receive and redress grievances for various stakeholders, including employees, customers, and communities, accessible through designated committees and the company’s website portal.

Key Performance Indicators (KPIs) Summary​

A review of material ESG metrics during the reporting period shows several key areas of focus:

Environmental and Waste Metrics:
The company reported a total waste generation of 3,223.79 metric tonnes in FY2025-26, down from 1,976.66 metric tonnes in FY2024-25. The entity ensured that all hazardous waste is disposed through authorized Treatment, Storage, and Disposal Facilities (TSDFs) using the SPCB online manifest system.

GHG Emissions:
The report details GHG emissions intensity per rupee of turnover: 1.92 tCO2e/Total Revenue from Operations in Million INR for FY2025-26. The company also reported a significant commitment to reducing its carbon footprint through initiatives like implementing a solar power project at manufacturing facilities.

Resource Efficiency:
The report details water usage, noting that the total volume of water consumption was 5,13,659.48 kilolitres for FY2025-26, resulting in a water intensity of 11.28 (Total Water Consumption / Revenue from Operations in Million INR).

Table: Key ESG Indicators (FY 2025-26)

Stakeholder and Fair Practices​

Gland Pharma actively engages with its various stakeholder groups to foster mutual growth. Key engagement categories include:

• Regulatory Bodies: Engagement occurs quarterly through compliance reports and statutory audits.
• B2C Stakeholders: Regular visits and customer satisfaction surveys are conducted for hospitals, distributors, and government facilities to enhance supply chain efficiency.
• Business Partners: Continuous engagement with C&F agents, vendors, and suppliers focuses on creating synergies and fostering innovation through co-creation.

The company also disclosed details regarding concentration of sales, noting that 32% of sales are conducted to the top 10 dealers/distributors, while 1.27% represent sales to dealers/distributors as a percentage of total sales.

GLAND Stock Price Movement​

Shares of Gland Pharma Limited slipped by 0.48% on Friday, finishing at ₹2502.9 after settling lower from the previous close. The equity traded a volume of 266,828 shares during the session.